AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06443242
Drug: Standard Medication Management (Control Group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
Trial: NCT05568147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When patients are randomized into the placebo group, they will receive placebo orally once a day.
Trial: NCT04969120
Drug: Placebo (0.9 sodium chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
Trial: NCT06454084
Drug: Acetylcholine Chloride
RxNorm normalized name: Acetylcholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilator solution
Trial: NCT06639672
Drug: Chemotherapy+PD-1 inhibitor+2.67Gy x 15f
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Trial: NCT06639672
Drug: Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Trial: NCT05888922
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Trial: NCT05888922
Drug: Vehicle solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Trial: NCT06565013
Drug: Cabenuva 600/900
RxNorm normalized name: Cabenuva 600/900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
Trial: NCT05392452
Drug: Standard insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin therapy according to local clinical practice.
Trial: NCT04878471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT05504746
Drug: SHEN26 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used.
Trial: NCT05504746
Drug: SHEN26 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
Trial: NCT05504746
Drug: SHEN26 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose.
Trial: NCT05504746
Drug: SHEN26 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days.
Trial: NCT04812483
Drug: standard therapy (without eltrombopag): HD-DXM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
Trial: NCT05713838
Drug: mFOLFOX-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
Trial: NCT06133270
Drug: NNC0560-0004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0560-0004, Oral administration (taken through the mouth)
Trial: NCT06133270
Drug: Placebo (NNC0560-0004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
Trial: NCT05019105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral matching placebo
Trial: NCT05202509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to resemble obicetrapib
Trial: NCT06110910
Drug: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
Trial: NCT05644301
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule, 200 mg, twice daily, for 12 weeks
Trial: NCT05644301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, no active substance, twice daily, for 12 weeks
Trial: NCT04912518
Drug: Placebo (Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
Trial: NCT06083571
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-inferiority
Trial: NCT06644326
Drug: 100mg IkT-148009 Wet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg wet tablet formulation
Trial: NCT05803772
Drug: APHD-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
Trial: NCT05803772
Drug: APH-012P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal jejunal-release placebo beads
Trial: NCT05348122
Drug: TG103,Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Trial: NCT05348122
Drug: TG103,QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Trial: NCT05348122
Drug: Placebo,Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Trial: NCT05348122
Drug: Placebo,QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Trial: NCT04976855
Drug: INDV-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration
Trial: NCT04976855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration
Trial: NCT04976855
Drug: SUBOXONE® sublingual film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
Trial: NCT05444439
Drug: empirical H.pylori regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
Trial: NCT06673641
Drug: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
Trial: NCT06673641
Drug: CABTREO Topical Gel
RxNorm normalized name: Cabtreo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
Trial: NCT06673641
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
Trial: NCT06675422
Drug: JY231 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.
Trial: NCT05772156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching saline placebo
Trial: NCT03984188
Drug: Theophylline ER
RxNorm normalized name: Theophylline ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg extended release (ER) low-dose theophylline taken orally daily
Trial: NCT03984188
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured methylcellulose placebo tablet taken orally daily
Trial: NCT05998759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous placebo weekly for 24 weeks.
Trial: NCT05720091
Drug: ZX-7101A 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a drug to treatment influenza in Chinese adults
Trial: NCT06534723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04741074
Drug: Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
Trial: NCT05647473
Drug: add-on low dose Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an additional 10g of astragalus per day.
Trial: NCT05647473
Drug: add-on high dose Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an additional 20g of astragalus per day.
Trial: NCT06096220
Drug: Application of 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
Trial: NCT06303752
Drug: ADRC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
Trial: NCT06303752
Drug: ADRC001 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
Trial: NCT04994990
Drug: OnabotulinumtoxinA Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
Trial: NCT04994990
Drug: OnabotulinumtoxinA Half Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
Trial: NCT06090799
Drug: SHR-3032 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose at varying dosage levels depending on treatment assignment
Trial: NCT05711797
Drug: ZX-7101A 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX-7101A a drug to treatment influenza in Chinese adults
Trial: NCT05284617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05003076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Trial: NCT06290713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
Trial: NCT04909333
Drug: 0.9% saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously.
Trial: NCT06024421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light yellow, film-coated tablet
Trial: NCT06493396
Drug: Opioid-free Analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
Trial: NCT03970031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching tablet
Trial: NCT06288893
Drug: SHEN211 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
Trial: NCT06493396
Drug: Opioid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Trial: NCT06639230
Drug: Sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
Trial: NCT05954624
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT05954624
Drug: ZSP1273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04998513
Drug: Medical Management Alone Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group.
Trial: NCT05384483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05824728
Drug: AGB101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-dose levetiracetam, 220 mg, extended release tablet
Trial: NCT04965064
Drug: Capecitabine and Neratinib.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
Trial: NCT06644794
Drug: Hormone replacement therapy cycle preparation for frozen embryo transfer
RxNorm normalized name: human embryo tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
Trial: NCT04782375
Drug: Stop group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: discontinue antiviral treatment
Trial: NCT05823441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers inhale 24 units of placebo spray
Trial: NCT05299424
Drug: CM336_group 1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 2a
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 2b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 3a
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 3b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 4a
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 4b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 5
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.